Cannabinoid Biology
Much has been learned since the 1982 IOM report Marijuana and Health.
Although it was clear then that most of the effects of marijuana were due to its actions
on the brain, there was little information about how THC acted on brain cells (neurons), which cells were affected by THC, or even what general areas of the brain were most affected by THC. In addition, too little was known about cannabinoid physiology to offer any scientific insights into the harmful or therapeutic effects of marijuana. That all changed with the identification and characterization of cannabinoid receptors in the 1980s and
1990s. During the past 16 years, science has advanced greatly and can tell us much more
about the potential medical benefits of cannabinoids.
Conclusion: At this point, our knowledge about the biology of marijuana and cannabinoids allows us to make some general conclusions:
o Cannabinoids likely have
a natural role in pain modulation, control of
movement, and memory.
o The natural role of cannabinoids in immune systems is likely multi-faceted
and
remains unclear.
o The brain develops tolerance to cannabinoids.
o Animal research demonstrates the potential for dependence, but this
potential is observed under a narrower range of
conditions than with
benzodiazepines, opiates, cocaine, or nicotine.
o Withdrawal symptoms can be observed in animals but appear to be mild
compared to opiates or benzodiazepines, such as diazepam (Valium).
Conclusion: The different cannabinoid receptor types
found in the body appear to play different roles in normal human physiology. In addition, some effects of
cannabinoids appear to be independent of those receptors. The variety of
mechanisms through which cannabinoids can influence human physiology underlies the variety of potential therapeutic uses
for
drugs that might act
selectively on different cannabinoid systems.
Recommendation 1: Research should continue into the physiological effects
of synthetic and plant-derived cannabinoids and the natural function of cannabinoids found in
the body. Because different cannabinoids appear to
have different effects, cannabinoid research should include, but not be restricted to, effects attributable to THC alone.
Efficacy of Cannabinoid Drugs
The accumulated data indicate a potential therapeutic value for cannabinoid drugs, particularly for symptoms such as pain relief, control of nausea and vomiting, and
appetite stimulation. The therapeutic effects of cannabinoids are best established for THC, which is generally one of the two most abundant of the cannabinoids in marijuana.
(Cannabidiol is generally the other most abundant cannabinoid.)
The effects of cannabinoids on the symptoms studied are generally modest, and in most cases there
are
more effective medications. However, people vary in their responses
to
medications, and there will likely always be a subpopulation of patients who do not respond well to other medications. The combination of cannabinoid drug effects (anxiety reduction, appetite stimulation, nausea reduction, and pain relief) suggests that cannabinoids would be moderately well suited for particular conditions, such as chemotherapy-induced nausea and vomiting and AIDS wasting.
Defined substances, such as purified cannabinoid compounds,
are preferable to plant products, which are of variable and uncertain composition. Use of defined cannabinoids
permits a more precise evaluation of their effects,
whether in combination or alone. Medications that can maximize the desired effects of cannabinoids and minimize the
undesired effects can very likely be identified.
Although most scientists who study cannabinoids agree that
the
pathways to cannabinoid drug development are clearly marked, there is no guarantee that
the
fruits of scientific research will be made available to the public for medical use. Cannabinoid- based drugs will only become available if public investment in cannabinoid drug research
is
sustained and if there is enough incentive for private enterprise to develop and market such drugs.
Conclusion: Scientific data indicate the potential therapeutic value of cannabinoid drugs, primarily THC, for pain relief, control of nausea and vomiting, and appetite stimulation; smoked marijuana, however, is a crude THC
delivery system that
also delivers harmful substances.
Recommendation 2: Clinical trials of cannabinoid drugs for symptom
management should be conducted with the goal of developing rapid-onset, reliable, and safe delivery systems.
Influence of Psychological Effects on Therapeutic Effects
The psychological effects of THC and similar cannabinoids pose three issues for the
therapeutic use of cannabinoid drugs. First, for some patients--particularly older patients
with
no previous marijuana experience--the psychological effects are disturbing. Those
patients report experiencing unpleasant feelings and disorientation after being treated with THC, generally more severe for oral THC than for smoked marijuana. Second, for
conditions such as movement disorders or nausea, in which anxiety exacerbates the
symptoms, the antianxiety effects of cannabinoid drugs can influence symptoms
indirectly. This can be beneficial or can create false impressions of the drug effect. Third,
for
cases in which symptoms are multifaceted, the combination of THC effects might provide a form of adjunctive therapy; for example, AIDS wasting patients would likely
benefit from a medication that
simultaneously reduces anxiety, pain, and nausea while
stimulating appetite.
Conclusion: The psychological effects of cannabinoids, such as anxiety reduction, sedation, and euphoria can influence their potential therapeutic value. Those
effects are potentially undesirable for certain patients and situations and beneficial for others. In addition, psychological effects can complicate the interpretation of other aspects of the drug's effect.
Recommendation 3: Psychological effects of cannabinoids such as anxiety reduction and sedation, which can influence medical benefits, should be evaluated in
clinical trials.
0 commentaires